BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29849807)

  • 21. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
    Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
    Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological, Immunohistochemical, and
    Mousavi M; Goodarzi MT; Kassaee SM; Jafari Heidarloo A; Fathi M
    Arch Iran Med; 2021 Feb; 24(2):86-93. PubMed ID: 33636974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
    Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
    Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis.
    Sameer AS; Nissar S; Fatima K
    Eur J Cancer Prev; 2014 Jul; 23(4):246-57. PubMed ID: 24614649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma.
    Bao F; Panarelli NC; Rennert H; Sherr DL; Yantiss RK
    Am J Surg Pathol; 2010 Dec; 34(12):1798-804. PubMed ID: 21107085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency.
    Nakano K; Yamamoto H; Fujiwara M; Koga Y; Tsuruta S; Ihara E; Oki E; Nakamura M; Ogawa Y; Oda Y
    Am J Surg Pathol; 2018 Feb; 42(2):172-182. PubMed ID: 28877066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
    Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
    Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.
    Carneiro da Silva F; Ferreira JR; Torrezan GT; Figueiredo MC; Santos ÉM; Nakagawa WT; Brianese RC; Petrolini de Oliveira L; Begnani MD; Aguiar-Junior S; Rossi BM; Ferreira Fde O; Carraro DM
    PLoS One; 2015; 10(10):e0139753. PubMed ID: 26437257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations.
    Wang T; Stadler ZK; Zhang L; Weiser MR; Basturk O; Hechtman JF; Vakiani E; Saltz LB; Klimstra DS; Shia J
    Fam Cancer; 2018 Apr; 17(2):225-228. PubMed ID: 28819720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic rearrangements in MSH2, MLH1 or MSH6 are rare in HNPCC patients carrying point mutations.
    Pistorius S; Görgens H; Plaschke J; Hoehl R; Krüger S; Engel C; Saeger HD; Schackert HK
    Cancer Lett; 2007 Apr; 248(1):89-95. PubMed ID: 16837128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of MLH1, MSH2 and MSH6 in the development of multiple colorectal cancers.
    Lawes DA; Pearson T; Sengupta S; Boulos PB
    Br J Cancer; 2005 Aug; 93(4):472-7. PubMed ID: 16106253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue expression of MLH1, PMS2, MSH2, and MSH6 proteins and prognostic value of microsatellite instability in Wilms tumor: experience of 45 cases.
    Diniz G; Aktas S; Cubuk C; Ortac R; Vergin C; Olgun N
    Pediatr Hematol Oncol; 2013 May; 30(4):273-84. PubMed ID: 23570624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of mismatch repair deficiency, CDX2, beta-catenin and E-cadherin expression in colon cancer: molecular characteristics and impact on prognosis and survival - an immunohistochemical study.
    Melincovici CS; Boşca AB; Şuşman S; Cutaş A; Mărginean M; Ilea A; Moldovan IM; Jianu EM; Neag MA; Bulboacă AE; Mihu CM
    Rom J Morphol Embryol; 2020; 61(3):715-727. PubMed ID: 33817713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
    van der Klift H; Wijnen J; Wagner A; Verkuilen P; Tops C; Otway R; Kohonen-Corish M; Vasen H; Oliani C; Barana D; Moller P; Delozier-Blanchet C; Hutter P; Foulkes W; Lynch H; Burn J; Möslein G; Fodde R
    Genes Chromosomes Cancer; 2005 Oct; 44(2):123-38. PubMed ID: 15942939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
    Jessup CJ; Redston M; Tilton E; Reimann JD
    Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation.
    McCarthy AJ; Capo-Chichi JM; Spence T; Grenier S; Stockley T; Kamel-Reid S; Serra S; Sabatini P; Chetty R
    J Pathol Clin Res; 2019 Apr; 5(2):115-129. PubMed ID: 30387329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defects of DNA mismatch repair in human prostate cancer.
    Chen Y; Wang J; Fraig MM; Metcalf J; Turner WR; Bissada NK; Watson DK; Schweinfest CW
    Cancer Res; 2001 May; 61(10):4112-21. PubMed ID: 11358834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results.
    Olkinuora A; Gylling A; Almusa H; Eldfors S; Lepistö A; Mecklin JP; Nieminen TT; Peltomäki P
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32660107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.